Scientific innovation improving patient outcomes

Ruvonoflast, our lead molecule, has demonstrated improvements in markers of inflammation, thrombosis and metabolism and has the largest clinical efficacy and safety dataset of any current NLRP3 inhibitor. Derived from proprietary NodThera chemistry, ruvonoflast achieves high tissue and brain penetrance with intracellular activation in key immune and cardiometabolic cells.

In a randomized, double-blind placebo-controlled study (NCT06129409), ruvonoflast significantly lowered high-sensitivity C-reactive protein (hsCRP) and other pro-inflammatory and cardiometabolic biomarkers in patients at high risk of cardiovascular disease. Read the press release for more information.

These clinical findings build on evidence from multiple preclinical cardiometabolic disease models, in which ruvonoflast reduced markers of systemic and vascular inflammation, reversed obesity and improved glucose homeostasis and insulin sensitivity. Learn more about the preclinical data here and here.

NT-0150 is a next-generation brain-penetrant NLRP3 inhibitor. NT-0150 has shown excellent preclinical efficacy, reducing central and peripheral inflammatory markers across multiple animal models. Phase 1 single- and multi-dose human clinical studies are underway.

NT-0249 is a potent NLRP3 inhibitor with excellent cerebrospinal fluid (CSF) penetration optimized for chronic inflammatory diseases of the body. NT-0249 is Phase 2-ready.